NewEdge Advisors’s Atossa Therapeutics ATOS Stock Holding History

NewEdge Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-333	Closed	-$1.75K	–	4192
2026 Q1	$1.75K	Hold	333	–	–	﹤0.01%	3831
2025 Q4	$2.95K	Hold	333	–	–	﹤0.01%	3807
2025 Q3	$4.33K	Hold	333	–	–	﹤0.01%	3575
2025 Q2	$4.15K	Hold	333	–	–	﹤0.01%	3456
2025 Q1	$3.37K	Hold	333	–	–	﹤0.01%	3403
2024 Q4	$4.72K	Hold	333	–	–	﹤0.01%	3255
2024 Q3	$7.6K	Sell	333 -667	-67%	-$13.5K	﹤0.01%	3022
2024 Q2	$17.9K	Buy	+1,000	New	+$22.1K	﹤0.01%	2659

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NewEdge Advisors's ATOS Position: Q2 2026 in Review

NewEdge Advisors sold out of Atossa Therapeutics (ATOS) in Q2 2026, closing a stake of 333 shares — an estimated $1.75K sold.

NewEdge Advisors first reported a position in ATOS in Q2 2024 and held it in 8 quarters. The position peaked at $17.9K in Q2 2024. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

NewEdge Advisors reported no remaining Atossa Therapeutics position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 333 Atossa Therapeutics shares in Q2 2026, an estimated $1.75K.
NewEdge Advisors first reported a position in Atossa Therapeutics in Q2 2024 and held it in 8 quarters.
NewEdge Advisors's Atossa Therapeutics position peaked at $17.9K in Q2 2024.
31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.